» Articles » PMID: 34374746

Safety and Acute Efficacy of Cryoballoon Ablation for Atrial Fibrillation at Community Hospitals

Abstract

Aims: Pulmonary vein isolation (PVI) using cryoballoon ablation (CBA) is an established procedure for treating symptomatic paroxysmal and persistent atrial fibrillation (AF). The safety and efficacy of PVI performed at community hospitals are unknown. We aimed to determine the safety and acute efficacy of PVI using CBA performed at community hospitals with limited annual case numbers.

Methods And Results: This registry study included 1004 consecutive patients who had PVI performed for symptomatic paroxysmal (n = 563) or persistent AF (n = 441) from January 2019 to September 2020 at 20 hospitals. Each hospital performed fewer than 100 CBA-PVI procedures/year according to local standards. Procedural data, efficacy, and complication rates were determined. The mean number of CBA procedures performed/year at each centre was 59 ± 25. The average procedure time was 90.1 ± 31.6 min and the average fluoroscopy time was 19.2 ± 11.4 min. Isolation of all pulmonary veins was documented in 97.9% of patients. The most frequent reason for not achieving complete isolation was development of phrenic nerve palsy. No hospital deaths were observed. Two patients (0.2%) suffered a clinical stroke. Pericardial effusion occurred in six patients (0.6%), two of whom (0.2%) required pericardial drainage. Vascular complications occurred in 24 patients (2.4%), two of whom (0.2%) required vascular surgery. Phrenic nerve palsy occurred in 48 patients (4.8%) and persisted up to hospital discharge in six patients (0.6%).

Conclusion: Pulmonary vein isolation procedures for paroxysmal or persistent AF using CBA can be performed at community hospitals with high acute efficacy and low complication rates.

Citing Articles

2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Tzeis S, Gerstenfeld E, Kalman J, Saad E, Sepehri Shamloo A, Andrade J J Arrhythm. 2024; 40(6):1217-1354.

PMID: 39669937 PMC: 11632303. DOI: 10.1002/joa3.13082.


Comparing pulsed field electroporation and radiofrequency ablation for the treatment of paroxysmal atrial fibrillation: design and rationale of the BEAT PAROX-AF randomized clinical trial.

Erhard N, Frison E, Asselineau J, Aouar B, Boveda S, Cochet H Europace. 2024; 26(5).

PMID: 38646926 PMC: 11068269. DOI: 10.1093/europace/euae103.


2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Tzeis S, Gerstenfeld E, Kalman J, Saad E, Sepehri Shamloo A, Andrade J J Interv Card Electrophysiol. 2024; 67(5):921-1072.

PMID: 38609733 DOI: 10.1007/s10840-024-01771-5.


2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Tzeis S, Gerstenfeld E, Kalman J, Saad E, Sepehri Shamloo A, Andrade J Europace. 2024; 26(4).

PMID: 38587017 PMC: 11000153. DOI: 10.1093/europace/euae043.


Single-shot technique of cryoablation for atrial fibrillation has comparable effective and safety outcomes compared to standard technique: insights from multiple clinical studies.

He C, Zhang W, Yin L, Sun M, Zhao Z, Ye G Front Cardiovasc Med. 2023; 10:1195492.

PMID: 37745124 PMC: 10512731. DOI: 10.3389/fcvm.2023.1195492.